Erlotinib HCl (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …

Erlotinib HCI (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
quinazoline-based agent that competes with adenosine triphosphate for binding with the …

Overexpression of the epidermal growth factor receptor (EGFR) is correlated with a poor
prognosis in several human malignancies. In addition, cancers overexpressing EGFR …

Research into the role of the human epidermal receptor growth factor receptor 1/epidermal
growth factor receptor (HER1/EGFR) in tumorigenesis has generated a new class of …

Pharmacokinetic and pharmacodynamic studies have an important role in the optimization
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …

Erlotinib (Tarceva) is an orally available selective small-molecule inhibitor of HER1/EGFR
tyrosine kinase with a 50% inhibitory concentration of 2 nM for purified tyrosine kinase. This …

Abstract Purpose: Erlotinib (Tarceva, OSI-774) is a potent and specific inhibitor of the
HER1/epidermal growth factor receptor (EGFR) tyrosine kinase. In phase II clinical studies …

In phase I trials in healthy volunteers and patients with refractory cancers, erlotinib (Tarceva)
was well tolerated and showed activity against non-small-cell lung cancer and other tumors …

Erlotinib is an orally available, reversible tyrosine kinase inhibitor of the epidermal growth
factor receptor. Encouraging activity as a single agent and in combination with other …

Importance of the field: The epidermal growth factor receptor (EGFR) is a cell surface
receptor for EGF and transforming growth factor-alpha which is overexpressed by a number …